Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will report sales of $2.12 billion for the current quarter, Zacks reports. Seven analysts have provided estimates for Regeneron Pharmaceuticals' earnings, with the highest sales estimate coming in at $2.51 billion and the lowest estimate coming in at $1.90 billion. Regeneron Pharmaceuticals reported sales of $2.05 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 3.4%. The firm is expected to announce its next quarterly earnings report before the market opens on Thursday, November 5th.
On average, analysts expect that Regeneron Pharmaceuticals will report full year sales of $8.27 billion for the current fiscal year, with estimates ranging from $7.73 billion to $9.27 billion. For the next year, analysts expect that the company will report sales of $9.68 billion, with estimates ranging from $8.42 billion to $11.92 billion. Zacks' sales calculations are an average based on a survey of research firms that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $7.16 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $5.59 by $1.57. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the previous year, the business earned $6.02 earnings per share. The firm's revenue was up 23.7% compared to the same quarter last year.
REGN has been the topic of a number of research analyst reports. Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $800.00 in a research report on Wednesday, August 5th. Cantor Fitzgerald raised shares of Regeneron Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $690.00 target price for the company in a research report on Monday, October 5th. Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $611.00 to $609.00 and set an "equal weight" rating for the company in a research report on Tuesday, October 13th. JPMorgan Chase & Co. reissued a "hold" rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 1st. Finally, SVB Leerink boosted their target price on shares of Regeneron Pharmaceuticals from $629.00 to $650.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. The company currently has a consensus rating of "Buy" and an average price target of $611.64.
Shares of REGN opened at $583.14 on Tuesday. The company's 50 day moving average price is $578.09 and its 200 day moving average price is $586.99. Regeneron Pharmaceuticals has a 52 week low of $294.86 and a 52 week high of $664.64. The company has a market capitalization of $62.04 billion, a PE ratio of 22.58, a PEG ratio of 1.43 and a beta of 0.50. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.12.
In related news, CFO Robert E. Landry sold 696 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $654.46, for a total transaction of $455,504.16. Following the completion of the sale, the chief financial officer now owns 23,973 shares in the company, valued at approximately $15,689,369.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Plew Daniel P. Van sold 27,109 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $610.89, for a total transaction of $16,560,617.01. Following the sale, the executive vice president now owns 36,854 shares of the company's stock, valued at approximately $22,513,740.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 164,823 shares of company stock valued at $99,036,079. Corporate insiders own 11.28% of the company's stock.
Several institutional investors have recently made changes to their positions in the stock. FMR LLC grew its holdings in Regeneron Pharmaceuticals by 47.2% during the 2nd quarter. FMR LLC now owns 12,463,480 shares of the biopharmaceutical company's stock worth $7,772,849,000 after acquiring an additional 3,999,170 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 48.4% in the 2nd quarter. BlackRock Inc. now owns 9,789,573 shares of the biopharmaceutical company's stock valued at $6,105,267,000 after purchasing an additional 3,191,724 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 22.3% in the 2nd quarter. Vanguard Group Inc. now owns 7,844,995 shares of the biopharmaceutical company's stock valued at $4,892,530,000 after purchasing an additional 1,429,765 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of Regeneron Pharmaceuticals by 355.5% in the 2nd quarter. California Public Employees Retirement System now owns 837,998 shares of the biopharmaceutical company's stock valued at $522,617,000 after purchasing an additional 654,007 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 40.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,706,789 shares of the biopharmaceutical company's stock valued at $1,064,438,000 after purchasing an additional 492,173 shares during the last quarter. Institutional investors and hedge funds own 85.89% of the company's stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Technical Indicators - What is a Golden Cross?
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Stocks That Robinhood Investors Got Right
The online investing app Robinhood has been a clear pandemic winner. As more Americans were forced to work from home, many made the decision to begin testing their investing skills by trading stocks. Robinhood appeals to millennial and/or novice investors for several reasons. First, the app makes it fun. You might say it “gamefies” stock trading. With commission-free trades, investors have an incentive to trade frequently. And many users of the app do just that.
The second reason is that it allows investors to buy partial (or fractional) shares. Although Robinhood is often associated with penny stocks, the app lets investors buy shares of “pricey” stocks like Tesla (NASDAQ:TSLA) without having to pay for a full share right away.
And data shows that Robinhood investors have a healthier risk appetite than other investors. And that appetite has increased since the start of the pandemic. This lines up to the time when investors had more time on their hands.
With that said, many Robinhood investors have been, quite frankly, using the app to engage in a legal form of gambling. I say this because trying to dive quickly in and out of the market in an attempt to capture a profit may work. But historically, it’s a path to ruin.
However there are two sides to every story. And the same is true of Robinhood investors. There are many examples of where these investors have gotten it right. In this presentation, we’ll show you eight examples of stocks that the market and Robinhood investors have gotten exactly right.
View the "8 Stocks That Robinhood Investors Got Right".